Here's What Wall Street Thinks About BridgeBio Pharma (BBIO)

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the Best Mid Cap Growth Stocks to Buy According to Hedge Funds. On August 5, BridgeBio Pharma, Inc. (NASDAQ:BBIO) reported results for its fiscal second quarter of 2025. Wall Street is bullish on the stock, and the share price has appreciated by around 5.5% since the announcement.

Recently, on August 13, Cantor Fitzgerald analyst Eric Schmidt FCA initiated coverage on BridgeBio Pharma, Inc. (NASDAQ:BBIO) with a Buy rating. The company reported $110.6 million in revenue, which nearly doubled from the previous quarter, driven by increased uptake. In addition, the management reported strong growth in Attruby, with 3,751 unique patient prescriptions as of August 1, 2025.

The company also released results from a new analysis from the ATTRibute-CM study, which reinforced its clinical strength. Results showed a 59% relative risk reduction for serious events in variant ATTR-CM patients treated with Attruby. BridgeBio Pharma, Inc. (NASDAQ:BBIO) ended Q2 with $756.9 million in cash, well-positioned to support Attruby’s growth and upcoming trial readouts.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biopharmaceutical company that discovers, develops, tests, and delivers transformative medicines for patients with genetic diseases.

While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.